10-Q: Zynex Reports Mixed Results in Q3 2024 Amidst Revenue Growth and Profit Decline

Zynex's Q3 2024 results show a slight increase in revenue but a decrease in net income compared to the same period last year.

Summary

• Zynex reported a slight increase in total net revenue to $50.0 million for the third quarter of 2024, compared to $49.9 million in the same period of 2023.
• For the nine months ended September 30, 2024, total net revenue reached $146.4 million, a 7% increase from $137.0 million in the same period of 2023.
• Device revenue decreased by 12% to $14.9 million in Q3 2024, while supplies revenue increased by 6% to $35.1 million.
• Net income for Q3 2024 was $2.4 million, down from $3.6 million in Q3 2023.
• Net income for the nine months ended September 30, 2024, was $3.6 million, a decrease from $8.5 million in the same period of 2023.
• Cash provided by operating activities was $10.3 million for the nine months ended September 30, 2024, compared to $11.6 million for the same period in 2023.
• The company's working capital was $58.5 million as of September 30, 2024, down from $69.3 million at the end of 2023.
• Device orders increased by 13% in Q3 2024 and 18% for the nine months ended September 30, 2024, compared to the same periods in 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While revenue increased, profitability declined, and there are concerns about internal controls. The company's future outlook is cautiously optimistic, but the identified weaknesses need to be addressed.

Positives

• Total net revenue increased slightly in Q3 2024 and by 7% for the first nine months of 2024.
• Device orders showed strong growth, increasing by 13% in Q3 and 18% for the nine months ended September 30, 2024.
• Supplies revenue increased by 6% in Q3 2024, indicating a growing customer base.
• The company has $37.6 million in cash and cash equivalents and $21.6 million in accounts receivable.

Negatives

• Net income decreased to $2.4 million in Q3 2024 and $3.6 million for the nine months ended September 30, 2024.
• Device revenue decreased by 12% in Q3 2024.
• Cash provided by operating activities decreased to $10.3 million for the nine months ended September 30, 2024.
• Working capital decreased to $58.5 million as of September 30, 2024.

Risks

• The company's primary change management controls were not designed and implemented effectively to ensure IT program and data changes affecting the company's financial IT applications and underlying accounting records are identified, tested, authorized, and implemented appropriately.
• There is a material weakness in internal control over financial reporting related to the valuation of accounts receivable.
• The company relies on a few significant vendors for its supplies, with four vendors providing 57% of supplies in Q3 2024.
• The company faces risks related to billing and reimbursement disputes with insurance providers.
• The company's forecasting model to estimate collections could change, which could impact results of operations and cash flows.
• Changes in the company's third-party payer mix could affect net revenue and related receivables.

Future Outlook

The company believes its cash and cash equivalents, along with anticipated cash flow from operations, will be sufficient to meet its working capital and capital expenditure requirements for at least the next twelve months.

Management Comments

• Management has concluded that the disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting.
• Management is committed to maintaining a strong internal control environment and is developing and implementing remediation plans to address the material weakness.

Industry Context

The medical device industry is subject to regulatory approvals and reimbursement challenges, which can impact revenue and profitability. Zynex operates in the electrotherapy and pain management sector, which is competitive and requires continuous innovation and effective sales strategies.

Comparison to Industry Standards

• Zynex's revenue growth of 7% for the first nine months of 2024 is moderate compared to some high-growth medical device companies, but it is important to consider the specific market segment and product offerings.
• Companies like Nevro Corp. and InMode Ltd. in the neuromodulation and aesthetic device sectors, respectively, have shown varying growth rates, with some experiencing higher growth but also facing different market dynamics.
• Zynex's profitability decline in Q3 2024 is a concern, as many medical device companies aim for consistent profit margins to support R&D and expansion.
• Compared to companies like Medtronic and Abbott, which are large, diversified medical device companies, Zynex is a smaller player with a more focused product portfolio, which can lead to different financial performance metrics.
• The material weakness in internal controls is a significant issue that needs to be addressed, as it can impact investor confidence and the reliability of financial reporting, which is a key concern for all public companies.

Related Party Transactions

• The company purchased 300,000 shares of its common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023 of $9.61 per share for $2.9 million.
• The company purchased 300,000 shares of its common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on June 13, 2023, of $8.62 per share for $2.6 million.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the material weakness in internal controls.
• Employees may be affected by changes in headcount and the company's performance.
• Customers may experience changes in product availability or service due to supply chain or operational issues.
• Suppliers may be impacted by changes in the company's purchasing patterns or financial stability.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• The company will implement remediation plans to address the material weakness in internal control over financial reporting.
• The company will continue to monitor the impact of COVID-19 on its operations and markets.
• The company will continue to execute its stock repurchase program.

Key Dates

Keywords

medical devices, electrotherapy, pain management, revenue, net income, device sales, supplies sales, financial results, internal controls, stock repurchase